NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

The sp has drifted down from the £2.10 mark when it was listed on the aim in April.
Rated a buy by Deutche Bank. With the rising junk food consumption, a climate not conductive to outside activity, and an ageing population, the fundementals are terrific-
in a grim sort of way. Consulting group Frost and Sullivan expects double -digit growth in the healthcare market in the Arabian Gulf between 2010 and 2018, with the United Arab Emirates (UAE) set to grow by 16.6% a year from $5.9bn in 2009 to $10.9bn by 2013. Here, demand is being spurred by government action to boost private-sector involvement in the sector, along with new laws in Abu Dhabi and Dubai which require citizens to have compulsory medical insurance.

This is all good for NMC Health. NMC operates four private hospitals, one day-care centre and eight pharmacies across the emerates. In the first half sales grew by 8.4%
to $238m, driven by higher patient volumes and better occupancy rates (up to 60.3%
from 51.6% a year earlier). In April NMC raised $168.1m when it listed in London at 210p a share. This is being used to build new sites. The Brightpoint maternity hospital and Mussafah day-patient facility in Abu Dhabi should open in December.
A hospital in Dubai investment park is slated for early 2013, and up to $200m is allocated for a development at Khalifa City to be tendered this year.NMC has also established a specialist distribution business (28% of EBITDA - earnings before interest,tax,depreciation and amortisation) that extends beyond medical products to coverconsumer goods, food and educational equiptment.

Deutche bank has a price target of £3.18p

watching closely.

NMC Health plc: Interim Results 2012
RNS
RNS Number : 9448K
NMC Health Plc
29 August 2012


Highlights



· Successful IPO on Premium Segment of the London Stock Exchange raising net proceeds of US$168.1m



· Double digit revenue and Adjusted EBITDA growth in the Healthcare division



· Healthcare occupancy increases to 60.3%, up from 51.6% for the same period in 2011.



· Newly developed "Centres of Excellence" in the Al Ain and Dubai Specialty Hospitals, where we have been centralising patient care in relation to specialist clinical areas, driving revenue and EBITDA growth



· Distribution division expanded trading activities to cover over 65,000 products



· Capital projects expected to open in FY2012/FY2013 progressing within budget:

o BR Medical Suites acquisition completed after period end in July 2012 (total capital expenditure cost: US$9m);

o The Dubai Investment Park warehouse facility, for the Distribution division, now open (capital expenditure in H1, 2012 US$5.7m; total capital expenditure cost: US$7.9m);.

o Brightpoint maternity hospital in Abu Dhabi expected to open in December 2012 (capital expenditure in H1, 2012: US$19m; total capital expenditure for project: US$70m);

o Mussafah day patient medical facility expected to open in Dec 2012 (capital expenditure in H1, 2012: US$0.7m; total capital expenditure for project: US$15m);

o The Dubai Investment Park medical facility expected to open in H1, 2013 (capital expenditure in H1, 2012: US$0.05m; total capital expenditure for project: US$25m).

o Khalifa City facility is expected to be tendered for civil works in Q3 2012 (capital expenditure in H1, 2012 US$ 1.4m; potential total capital expenditure for project: US$ 200m.



· Total Capital Expenditure during H1, 2012 was US$37.1m, of which US$27.1m relates to current capital development projects.



· Cash balance of US$276.6m, net cash position of US$24.8m



· Outlook remains positive and the Group continues to trade in line with the board's expectations for the full year




http://www.moneyam.com/action/news/showArticle?id=4434306

NMC Health scores five year contract at new hospital in UAE
Mon 26 Nov 2012

NMC - NMC Health

Latest Prices
Name Price %
NMC Health 178.20p +4.95%

FTSE 250 11,855 -0.28%
FTSE 350 3,088 -0.49%
FTSE All-Share 3,024 -0.48%
Health Care Equipment & Services 3,703 -0.25%

LONDON (SHARECAST) - Shares in healthcare provider NMC Health have risen after it revealed that its subsidiary was awarded a five-year contract to operate and manage the new Sheikh Khalifa General Hospital in Umm Al Quwain, in the United Arab Emirates (UAE).

The company's fee income will total between $4.0m and $5.4m in the first year of operation, if it meets certain criteria.

NMC will also be managing all support services including pharmacy, equipment sterilisation and ambulance services as well as hospital administration.

At the end of the five years term of the agreement, the executive management team is expected to train and hand over their responsibilities to new management to be employed by the UAE Ministry of Presidential Affairs.

Under the terms of the contract, all of the capital expenditure, hospital and staff expenses will be met by the ministry.

The hospital is expected to open on December 2nd and will offer a wide range of clinical and healthcare services including general medicine and surgery, emergency and intensive care, and dental services. It will have a capacity of 55 rooms for out-patient consultation, examination and treatment, as well as nine operating theatres and a total of 205 in-patient rooms.

Dr B. R. Shetty, Chief Executive Officer, said: "We are delighted to have been awarded the contract to operate and manage the newly constructed Sheikh Khalifa General Hospital in Umm Al Quwain on behalf of the UAE Ministry of Presidential Affairs. This is the fourth emirate in which NMC Healthcare will operate, and consolidates our position as the leading pan-UAE private healthcare operator.

"This contract is a new income stream for the group, providing healthcare management services to a third party, and the award of the contract is a testament to the reputation of NMC Healthcare which has built up across the UAE over nearly four decades.

"We look forward to working with the UAE Ministry of Presidential Affairs in making the Sheikh Khalifa General Hospital a success. We also look forward to caring for the population of Umm Al Quwain and the Northern Emirates, by providing first class healthcare services to them."

The share price rose 6.01% to 180p by 13:30.

Still watching this one.

Still watching

NMC Health on target for full year
By Michael Millar

Thu 03 Jan 2013

NMC - NMC Health

Latest Prices
Name Price %
NMC Health 200.00p 0.00%

Health Care Equipment & Services 3,906 +0.32%

LONDON (SHARECAST) - NMC Health, which provides healthcare services in the United Arab Emirates, said it expected full year results be in line with expectations.

Its trading update said both revenue and profit levels for the year to the end of December were in line with expectations, while its net debt position and cash balance were as projected and capital expenditure remained on budget.

The firm reported work was progressing on its four major capital projects and the costs of each of these remained on budget.

These include hospitals in Abu Dhabi, Khalifa City and Dubai, as well as the Musaffah Day Patient Centre.

Chief Executive, Dr B.R.Shetty, said NMC's financial position remained good.

"Revenue and occupancy remained strong in the group's operational healthcare facilities during the second half of the year and our Distribution Division growth has continued as expected in the latter part of the second half of the financial year," he said.

"We are excited by the opportunities that we believe will be available to build on the group's good reputation in the UAE, with the opening of three of our four capital projects during the 2013 financial year," he added.

The firm will release its full year results for the twelve months ended 31st December on 26th February 2013

Making a good recovery

:-))

Final Tues 26th, Brilliant recovery.

http://www.barchart.com/opinions/stocks/NMC.LS

Full year group revenue rises 10.5 per cent at NMC Health
Tue 26 Feb 2013

NMC - NMC Health

Latest Prices
Name Price %
NMC Health 269.25p +0.09%

FTSE All-Share 3,308 -1.14%
FTSE Small Cap 3,688 -0.73%
Health Care Equipment & Services 3,948 -0.95%

LONDON (SHARECAST) - Group revenue rose 10.5 per cent to 490.1m dollars in the full year to December 31st at NMC Health, the healthcare provider operating across the United Arab Emirates.

In a financial report for the full year, the group reported that revenue in the healthcare division was up 15% to $251.6m compared with the full year 2011. This was driven principally by occupancy levels, which were up 750 bps to 60.5% compared with the full year 2011.

Distribution revenue was up 7.0% to $271.1m principally driven by continued expansion of product lines.

EBITDA (earnings before interest, tax, depreciation and amortisation) was up 12.9% to $79.6m compared with the full year 2011.

Business highlights for the year included the completed acquisition of BR Medical Suites in Dubai for a cash consideration of $9.0m. The company was also awarded a five year contract to manage the Sheikh Khalifa General Hospital in Umm Al Quwain.

Dr Shetty, Chief Executive Officer of NMC Health, commented: "This has been a pivotal year for NMC Health, and we are proud to have been the first Abu Dhabi-based business to list on the Premium Segment of the London Stock Exchange.

“Our full year results show that we have made strong progress across our existing facilities during 2012. 2013 will again be a year of transformation as we expect to open three of the four capital projects, which we committed to as part of our IPO, and which will help drive our future growth.”

NMC Health’s share price was up 0.37% to 270p at 12:43 on Tuesday.

The naked trader 27 Feb -


I've bought some more NMC Health (LON:NMC) at 265.6. Off the radar for most this one but I've already made profits of more than 30% on it and happy to average up with some more.

Excellent results yesterday with big rising profits and a confident outlook - it is very close to gaining entry to the FTSE 250 if it goes a little higher and could enter next month or in June which would give it another lift.

And finally as you know I am a big fan of topping up shares I already hold that have already gone up a lot.

NMC Health PLC (NMC:LSE) set a new high during today's trading session when it reached 308.00. Since the IPO on Apr 02, 2012, the share price is up 43.33%.

Great chart.

NMC Health records increase in quarterly revenues
Tue 30 Apr 2013


NMC Health records increase in quarterly revenues LONDON (SHARECAST) - NMC Health has posted an 11 per cent year-on-year increase in first quarter revenues to 139m dollars, bolstered by demand for specialist clinical services in its healthcare division.

The chain, which has branch hospitals in Dubai, Sharjah and Al Ain, said it was trading in line with expectations for revenue and earnings before interest, tax, depreciation and amortisation (EBITDA).

Its healthcare division’s occupancy rates increased 64% in the quarter, compared to 55.7% the year earlier, despite an additional 31 beds.

Revenue in the Distribution division increased by more than 10% to $77.3m, compared with the three months to March 31st 2012. Gross margin levels remain as expected.

The group had $217.6m of cash and bank deposits, and a total group debt of $302.6m as at March 31st 2013, both broadly in line with management expectations.

"NMC Health has made a strong start to the year. Occupancy levels in the healthcare division continue to increase driven by a strong demand for our services in the region," Chief Executive Bavaguthu Raghuram Shetty said.

"The Distribution division continues to perform well in good macro-economic conditions in the UAE. We are looking forward to opening our day patient centre in Mussafah in the coming weeks and I am pleased with the progress we are making with our other capital projects."

The group added that its capital projects remain on budget. Projects include the Brightpoint Women's Hospital, Mussafah day patient medical centre, Dubai Investment Park General Hospital and Khalifa City Specialty Hospital.

The share price fell 3.23% to 326.90p by 09:35 Tuesday.

===================================================
30 Apr 15:22 NMC Health PLC Numis Downgrades

LONDON (ShareCast) - NMC Health continued to fall one day after it posted an 11 per cent year-on-year increase in first quarter revenues to 139m dollars, bolstered by demand for specialist clinical services in its healthcare division. The figures failed to impress Numis Securities, prompting a downgrade from 'buy' to 'hold'.

NMC Health: Numis upgrades to buy with its target price at 350p

Ex divi 29 May payment 4 July 4.1p

Consensus recommendation



As of May 24, 2013, the consensus forecast amongst 3 polled investment analysts covering NMC Health PLC advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Apr 03, 2013. The previous consensus forecast advised investors to purchase equity in NMC Health PLC.

Share price forecast


The 3 analysts offering 12 month price targets for NMC Health PLC have a median target of 350.00, with a high estimate of 379.00 and a low estimate of 338.00. The median estimate represents a 17.06% increase from the last price of 299.00.

NMC Health: Numis ups target price from 500p to 560p and reiterates a buy recommendation.

In todays mail newspaper - Dubai decision lifts NMC Health.

More old codgers are retiring in Dubai and its easy to see why. Cold and wet weather is unlikely to ever bother them again and the heat will help their various ailments, so prevalent in the UK , totally alleviated.
Dubai's small population and numerous medical facilities in the private and public sector also mean that long waiting lists for a hospital bed are almost unheard of in the country.
Savings and pensions are probably better off invested in the Emirates for tax purposes too and, with strict alcohol laws reducing crime in the region to absolute minimum levels, the seven-plus hour flight on Virgin Atlantic out of Gatwick for many is well worth enduring.
Dubai was in the news yesterday after shares of NMC Health, the first Abu Dhabi company to be listed on the LSE in April 2012, soared 39.5p to a record 420p after the Dubai government made health care insurance mandatory for all residents and visitors.

Director Deals - NMC Health PLC (NMC)

Jonathan Bomford, Non Executive Director, bought 10,000 shares in the company on the 28th November 2013 at a price of 413.45p. The Director now holds 10,000 shares. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com

In Shares - forecasts for 2014 are looking conservative given the situation in Dubai.
The company will manage six hospitals in the United Arab Emirates next year as well as two day care patient centres, one medical centre and eight pharmacies. It also has a distribution business which supplies pharmaceuticals, food and scientific and medical products. Both brokers who follow NMC are bullish.

Moving up over the last few days.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 440.00. Over this period, the share price is up 143.33%.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 450.00. Over this period, the share price is up 161.34%.

2013 Full-Year Trading Update

RNS


RNS Number : 8191W

NMC Health Plc

03 January 2014













NMC Health Plc - 2013 Full-Year Trading Update







London, 3 January 2014: NMC Health Plc ("NMC") (LSE:NMC), the leading private sector healthcare provider operating across the United Arab Emirates, today provides a trading update for its 2013 financial year.



Trading Update

NMC expects to report results, in line with expectations, for the twelve months ended 31 December 2013. The net debt position, capital expenditure and operational cash flow are also anticipated to be in line with management expectations.



Projects update

NMC opened the Mussafah Day Patient Centre in July 2013 in close proximity to both the rapidly expanding Mohammad bin Zayed City (MBZC) suburb and the Mussafah industrial area of Abu Dhabi. The new facility is connected to a shopping mall and will cater to the growing local population for both outpatient consultancy services and minor surgical procedures. The facility will act as a referral point to our existing Specialty Hospital in central Abu Dhabi, some 35km away, and in the longer term to our new Khalifa City Hospital, some 10km away. We are pleased with progress and patient flow since opening.



Meanwhile, all our other projects including the Dubai Investment Park General Hospital, Brightpoint Women's Hospital, Al Ain Medical Centre and the Khalifa City Hospital are progressing towards their respective opening dates, as communicated earlier in 2013.







Dr B.R.Shetty, Chief Executive Officer, commented:



"I am pleased with NMC's growth over the past year in both our healthcare and distribution divisions. Management will continue to work towards increased efficiencies and operational gearing in existing operations and a smooth introduction of new assets.



The opening of our Mussafah Day Patient Centre in July 2013, was the first in a string of new near-term additions to our healthcare portfolio in the UAE. In 2014 we will see the opening of two hospitals and a medical centre, followed by the opening of our largest hospital in H1 2015.



Management and the team at NMC have worked very hard since the IPO to deliver this organic expansion program. Our strategy has been reinforced by the strong population and economic growth seen in the UAE over the past year and the recent adoption of mandatory healthcare insurance in Dubai. Consequently, I look forward to a rewarding 2014 for NMC and its shareholders"







Calendar



Full-year financial results for the twelve months ended 31 December 2013 will be issued on 25 February 2014. NMC will host an analyst/investor webcast on that day. Further details will be announced in due course.

NMC Health's growth strategy in UAE rolls on

By Giles Gwinnett

January 03 2014, 8:33am
The FTSE 250 group says this year will see the two hospitals and a medical centre open, while its largest hospital will open its doors in the first half of 2015
The FTSE 250 group says this year will see the two hospitals and a medical centre open, while its largest hospital will open its doors in the first half of 2015


United Arab Emirates (UAE) private health care group NMC Health (LON:NMC) is looking forward to further organic expansion in 2014.

The FTSE 250 group says this year will see the two hospitals and a medical centre open, while its largest hospital will open its doors in the first half of 2015.

In July this year, the firm opened a day patient centre close to both the rapidly expanding Mohammad bin Zayed City (MBZC) suburb and the Mussafah industrial area of Abu Dhabi.

Chief executive Dr B R Shetty said the firm's strategy had been boosted in 2013 by the strong population and economic growth in the UAE.

Final results for the year to end December are expected to be "in line with managment expectations"

Shetty also noted the recent adoption of mandatory healthcare insurance in Dubai.

The firm employs over 4,500 people across the UAE and operates a healthcare and trading business.

Shares dipped 1.94% to stand at 440.20p each.

Full Year Results ending 2013

http://www.moneyam.com/action/news/showArticle?id=4761378

25 Feb Numis 560.00 Buy

Dividend Timetable and AGM notice

RNS


RNS Number : 8956A

NMC Health Plc

25 February 2014








NMC Health Plc - Dividend Timetable and AGM








London, 25 February 2014: NMC Health Plc ("NMC" or the "Company") (LSE:NMC), the leading independent healthcare provider operating across the United Arab Emirates, announces details of its dividend timetable and date of its 2014 Annual General Meeting.



Further to the 2013 financial year preliminary results announcement of the Company released this morning, in which the Board announced that it is recommending a final dividend of 4.4 pence per ordinary share, the Company hereby confirms the following dividend timetable:



· Ex-dividend date - 28 May 2014



· Record date - 30 May 2014



· Payment date - 3 July 2014





Payment of the final dividend remains subject to shareholder approval at the Company's 2014 Annual General Meeting of the Company to be held on Thursday 26 June 2014, at 2:00 pm at the offices of Allen & Overy LLP, One Bishops Square, London E1 6AD.

NMC Health: Jefferies increases target price from 430p to 589p and keeps a buy recommendation

NMC Health: Numis raises target price from 560p to 620p reiterating a buy recommendation.

Interim Management Statement


Highlights

· Total Consolidated Group Revenue reached US$ 153.8m, a 10.6% increase compared to Q1, 2013



· Occupancy levels in our hospitals increased to 71.3% in Q1 2014 (+730bps year on year).



· Our projects remain on track and we expect to open the DIP and Brightpoint Hospitals in H1, 2014.



· NMC reached distribution agreements with leading brands, including; Luna and Super-Max.



· Group net debt reached US$ 69.4m, as of Q1 2014 end, which was in line with management expectations





http://www.moneyam.com/action/news/showArticle?id=4799793

Ex dividend Wed 28 May 4.4p

2014 Half-Year pre-close statement

RNS


RNS Number : 6486K

NMC Health Plc

26 June 2014













NMC Health Plc

Opening of two new hospitals and 2014 Half-Year pre-close statement





London, 26 June 2014: NMC Health Plc (LSE:NMC / 'NMC'), the leading integrated private sector healthcare operator in the United Arab Emirates, today announces its trading update for the period from 31 December 2013 to 25 June 2014 and that both Brightpoint Womens Hospital and DIP General Hospital are expected to open and to start receiving patients in the first week of July 2014.



Trading Update

NMC expects to report results and a financial position in line with management expectations for the six months ended 30 June 2014.



Opening of Brightpoint and DIP Hospitals

NMC is pleased to announce that it expects to open Brightpoint Womens Hospital in Abu Dhabi (100 bed capacity) and DIP General Hospital in Dubai (60 bed capacity) in the first week of July 2014. All Regulatory licences have been received to start seeing patients in relation to Brightpoint Womens Hospital and DIP General Hospital.



As a result, NMC has achieved two further major milestones having now completed four out of the five additional healthcare facilities which were committed to during its IPO in April 2012 (1: BR Medical Suites, 2: NMC Day Surgery in Mussafah, 3: Brightpoint Womens Hospital and 4: DIP General Hospital).



With the start of operations at these new assets in the first week of July 2014, the bed capacity available to the group will increase by 52%, an increase of 160 beds (a 55% increase in capacity in Dubai and a 50% increase in Abu Dhabi Emirate). This brings total bed capacity to 470 beds across the UAE, of which 64% are in Abu Dhabi and 36% in Dubai.



Both these new healthcare facilities will commence operations with highly experienced teams of medical and administrative staff, which we will continue to expand along with the growth in operations.



Brightpoint, will be the first private sector womens hospital in Abu Dhabi. It occupies a modern building in a strategic city centre location accessible through several key traffic arteries and with ample parking space available for the convenience of patients.



DIP General Hospital will be a needed addition to the rapidly growing residential and commercial areas around Dubai Investment Park, Dubai World Central and the planned Dubai Expo zone. DIP is also a timely expansion for NMC ahead of Dubai's roll-out of mandatory healthcare insurance later this year, where an estimated 66% of the 3m population remains uninsured according to Dubai Health Authority (DHA).



The development of our largest capital project, Khalifa City Hospital, and the Sanaiya Medical Center in Al Ain, are both progressing well and remain on track to open in H1, 2015 and H2, 2014 respectively.



Annual General Meeting

NMC is today holding its Annual General Meeting commencing at 2.00 pm. The result of voting on the resolutions being considered at the Annual General Meeting will be announced following that meeting.





Dr B.R.Shetty, Chief Executive Officer, commented:



"The Management team and the Board are pleased with the group's performance during the first half of 2014 and in particular with the completion of two of our largest and most ambitious expansion projects, the Brightpoint and DIP Hospitals.



I look forward to the imminent opening of these two hospitals and the long-term growth they will bring to our operations by expanding our geographic presence, increasing our service offering and our competitive advantage in the fast growing UAE market."



Interim Results



Interim results for the six months ended 30 June 2014 will be announced on 19 August 2014. NMC will host an analyst/investor webcast on that day.



Further details will be announced in due course.

FTSE 250 movers: NMC Health rises on CEO purchase

Mon, 30 June 2014


NMC Health continued to surge, extending Friday's gains after its Chief Executive Officer and founder, B. R. Shetty, purchased 10m shares from its largest shareholder at a price of 500p per share.

At the end of last week Numis Securities reiterated its 'buy' rating following the group's pre-close trading statement issued the previous day. The group has two new hospitals that were expected to be opened in the first half, although it confirmed this would be marginally late with their opening now scheduled for the first week of July.

A £50 million pound purchase by Chief Executive Officer and founder, B. R. Shetty

HALF-YEARLY FINANCIAL REPORT

H1 2014 Highlights - A strong start to the year



· Group Revenues increased by 15.1% year-on-year (YoY, compared to H1 2013) to reach US$ 314.3m



· Group EBITDA was US$ 52.0m (+12.7% YoY) resulting in a Group EBITDA margin of 16.5%



· Healthcare division patients increased by 13.7% YoY, achieving a good increase in occupancy despite a rise in operational beds to 277 (+16 beds) and delivered a moderate expansion in revenue per patient to US$ 114



· Distribution division's growth was supported by new product introductions and increased sales effort with stock keeping units (SKU's) exceeding 81,000



· Operating cash flow increased by 21.7% YoY to US$ 41.4m



· Net debt increased to US$ 99.6m on project development progress and remained in line with management expectations. Cash and cash equivalents amounted to US$ 227.5m with a total debt balance at US$ 327.1m



· Two major milestones were achieved with the opening of Brightpoint Women's Hospital and NMC Dubai Investment Park General Hospital immediately after the end of H1 2014, in July 2014



http://www.moneyam.com/action/news/showArticle?id=4870633

18 Sep Jefferies... 600.00 Buy

NMC Health: Investec initiates with a target price of 610p and a buy recommendation.

Interim Management Statement and Management Change

Financial and operational highlights

· Total Consolidated Group Revenue reached US$ 161.2m, an 18.1% increase compared to Q3, 2013



· Healthcare division continues to benefit from increased demand for specialist clinical services



· Distribution division trading well in good macro-economic conditions in the UAE



· Occupancy levels increased to 72.8% in Q3 2014 from 60.2% Q3 2013



· Brightpoint Women's Hospital and NMC Dubai Investment Park General Hospitals opened in July 2014 and other projects remain on track.



· Group net debt reached US$ 105.2m, as of Q3 2014 end, which was in line with management expectations



Senior management changes



· Mr Binay Shetty to step down from his role as Chief Operating Officer as of 31 December 2014. Binay will be taking up a new role in the Shetty Family Investment Office and remain a Non-Executive Director of NMC Health plc







http://www.moneyam.com/action/news/showArticle?id=4911835

28 Oct Jefferies... 600.00 Buy
28 Oct Numis 620.00 Buy

Interesting price is up and volume down.

NMC Health: Citi initiates with a target price of 520p and a neutral rating.

3 Feb Investec 610.00 Buy

Update of group strategy.

////////////////////////////////////////////////////////////////////////////////////////////////

16 Feb Jefferies... 600.00 Buy

Full year results

Acquisition of Clinica Eugin
RNS
RNS Number : 6648F
NMC Health Plc
24 February 2015





24 February 2015

NMC HEALTH PLC ANNOUNCES THE ACQUISITION OF LEADING GLOBAL FERTILITY CENTRE

NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated private healthcare provider operating across the United Arab Emirates, is pleased to announce that it has entered into an agreement to acquire 86.4% of issued share capital of Clinica Eugin ('Eugin'), a leading global fertility treatment provider based in Barcelona, Spain, for an Enterprise Value of €143m. Eugin is one of the largest fertility clinics in Europe and the established leader in cross-border fertility treatment with patients from the largest Western European countries, as well as the MENA region. The shares are to be acquired from ProA Capital, Eugin's founders and members of the Eugin management team.

The acquisition of Eugin allows NMC to achieve several key elements of its recently updated Group Strategy and is supported by a strong strategic rationale:

· Eugin is a leading IVF centre of excellence with world-leading technology and expertise as well as strong brand recognition

· Brings leading global expertise and technologies in fertility services to NMC's network in the UAE and strongly complements existing NMC women's health services

· Accelerates the development of NMC into a centre of clinical excellence for women's health and will allow NMC to establish a foothold in the UAE medical tourism market

· Significant potential for revenue synergies from growing Eugin's franchise in the UAE and the broader GCC/MENA region

· Transaction expected to be significantly accretive in Year 1 with positive effect on margins and attractive ROIC

· Eugin's strong and experienced management team have agreed to remain at the Company, limiting potential integration risk

Furthermore, in line with NMC's Group Strategy, the Company is also in discussion with multiple parties regarding potential acquisition opportunities in the UAE and GCC region, which would allow NMC to increase its scale across the region as well as further maximise operational synergies. These discussions remain at a preliminary stage and there is no certainty that any of these discussions will lead to additional announced transactions.





Dr. B.R. Shetty, Chief Executive Officer, commented:

"The acquisition of Eugin represents a unique juncture in the history of NMC, combining the leading UAE hospital franchise with a leading global fertility franchise. This transaction offers NMC the opportunity to become the leading integrated women's health provider from fertility through obstetrics and paediatrics in the UAE, and also establishes a foothold for the Company in the growing medical tourism market. The acquisition is expected to be accretive within the first year, and further progresses NMC's strategy of creating centres of excellence across a number of clinical specialties".



Market Opportunity in the UAE fertility sector

Infertility is a growing medical issue within the UAE and, according to Frost & Sullivan ('F&S'), it is estimated that the total fertility rate (number of children per woman) in the country has declined from 2.7 in the year 2000 to 1.7 in 2010, with approximately one in six couples experiencing fertility problems. Furthermore, there is an acute shortage of world class fertility treatment facilities in the country with F&S estimating a supply/demand shortfall of 8,500 IVF cycles in 2013, which represented over 50% of the total demand for IVF treatment in that year.

The infertility market in the UAE is also expected to be driven by the growing medical tourism sector in Dubai. Dubai Health Authority has announced plans to attract 500,000 medical tourists by 2020, generating over $700m in revenues. As of 2014, infertility procedures have also been identified by Dubai Health Care City's (DHCC) recent survey as the leading treatment sought by medical tourists visiting the Emirate.



Information on Clinica Eugin

Based in Barcelona and founded in 1999, Eugin is amongst the largest European providers of fertility treatments, in terms of the number of cycles performed annually, and has the largest egg bank in Europe providing c.10% of donor IVF treatments in Europe. The Company is also the leader in cross-border fertility treatments in Europe. In 2014, the clinic treated more than 5,000 patients and carried out over 8,000 cycles. The clinic offers a full range of fertility treatments including intra-uterine insemination (IUI), in-vitro fertilisation (IVF), intra-cytoplasmic sperm injection (ICSI), fertility preservation and genetic screening.

Over 95% of Eugin's patients are referred from outside Spain with France (55%), Italy (17%), Switzerland (4%), MENA (3%) and the UK (2%) representing the main countries of origin for the patients. Almost all of Eugin's revenues are derived from privately insured or cash pay patients.

Eugin has been majority-owned by ProA Capital since 2010. Eugin's current senior management, Andres Rebage (General Operational Manager) and Dr. Valerie Vernaeve (General Medical Manager), have been with Eugin for several years and have agreed to continue to manage, and retain an investment, in the business.

For the twelve months ended 31 December 2014, Eugin reported revenues of €34.3m, EBITDA of €14.0m and EBITDA margins of 41.0%. As of 31 December 2014, Eugin had gross assets of €59.0m and approximately 230 employees.



Financing and Financial Impact on NMC

NMC will finance the transaction using existing cash and credit facilities. NMC expects to retain post transaction, a net debt to EBITDA level allowing the Company financial flexibility for future growth initiatives. In this transaction, NMC has not utilised any of the funds made available through the US$ 825m facility announced on 16 February 2015.

Excluding synergies, the transaction is expected to be significantly accretive to NMC's EPS.



Additional Information on the Transaction

The Transaction is subject to customary terms and conditions. The transaction was signed and closed simultaneously on 23 February, 2015.

HSBC is acting as Financial Advisor and Evercore Partners is acting as Strategic Advisor to NMC. In addition, NMC is being advised by Allen & Overy and PwC.

NMC Health plc will host a webcast and conference call presentation for investors and analysts today at 14.00 UK time. There will be a short presentation by management covering the FY 2014 results and this transaction followed by a Q&A session.



The call will be hosted by:

Mr Prasanth Manghat, Deputy CEO

Mr Suresh Krishnamoorthy, Chief Financial Officer

Mr Roy Cherry, Head of Strategy & IR







Date and time:

Date Tuesday 24 February 2014

Time 14.00 GMT (09.00 EDT, 18.00 UAE)









- ends -

24 Feb Investec N/A Buy
24 Feb Numis 620.00 Buy

25 Feb Jefferies... 800.00 Buy

Director/PDMR Shareholding
RNS
RNS Number : 9864F
NMC Health Plc
26 February 2015













NMC Health plc



NOTIFICATION MADE IN ACCORDANCE WITH RULE 3.1.4 (1) (a) OF THE

DISCLOSURE AND TRANSPARENCY RULES





London, 26 February 2015: NMC Health plc (LSE:NMC) ('NMC'), the leading integrated private sector healthcare operator in the United Arab Emirates, announces that it was notified on 26 February 2015 that the following director purchased ordinary shares of 10p each in the Company ("Shares"). The Shares were purchased at a price of 558 pence per Share.



Director
Position
No. of Shares purchased

Heather Lawrence
Independent Non-Executive Director
1,790




Following this purchase, Mrs Lawrence has an interest in a total of 6,347 Shares, representing approximately 0.01% of the issued share capital of the Company.

Naked Trader today - I've bought into NMC Health (LON:NMC)



I really like the middle east medcare sector at the moment. There is a massive catalyst for growth in that Dubai is rolling out mandatory healthcare insurance over the next couple of years which should see shares in NMC continue to rise - and also that of Al Noor which I bought last time and have a load of from lower.

The shares don't on the face of it look cheap - but remember the market looks forwards and it is eyeing up the benefits due from mandatory heathcare.

I think both NMC and ANH will boom (boom shake the room). (Tick, tick, tick.. boom...) (that's enough aged dance music references)

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 658.00. Over this period, the share price is up 19.54%.

18 Mar Numis 800.00 Buy

Two acquisitions

29 Apr Investec N/A Buy
29 Apr Numis 880.00 Buy

30 Apr Investec 900.00 Buy

5 May Jefferies... 1,000.00 Buy

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 869.50. Over this period, the share price is up 86.59%.

Acquisition of Pro Vita

Statement re Possible Offer
RNS
RNS Number : 8442B
Al Noor Hospitals Group PLC
09 October 2015



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION



THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER WILL BE MADE



FOR IMMEDIATE RELEASE

October 9th, 2015



The Board of Al Noor Hospitals Group Plc (the "Company") notes the recent media speculation in relation to the Company and confirms that it has received an approach from NMC Health Plc ("NMC") regarding a possible offer.



In accordance with Rule 2.6(a) of the Code, NMC is required, by not later than 5.00 p.m. on November 6th, 2015, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

NMC Health remains committed to a combination
StockMarketWire.com
NMC Health notes the announcement today by Al Noor Hospital Group and Mediclinic International Ltd.

"This confirms our belief in the competitiveness of our initial possible offer and that the combination of NMC and Al Noor has the strongest strategic and financial rationale for all stakeholders," it said in a statement.

"We reiterate our commitment to this opportunity despite the lack of meaningful engagement from the Board of Al Noor.

"We plan to issue a further announcement in due course. We would urge shareholders to take no action at this time."



At 9:22am:
(LON:ANH) Al Noor Hospitals Group PLC share price was +134p at 1128.5p
(LON:NMC) NMC Health PLC share price was +20p at 828.5p


Story provided by StockMarketWire.com

Company News

NMC Health abandons bid for Al Noor Hospitals

Mon, 16 November 2015




(ShareCast News) - NMC Health has abandoned its bid for Al Noor Hospitals, meaning South Africa's Mediclinic International looks set to clinch a deal with the Abu Dhabi-based healthcare operator.
Al Noor confirmed in early October that it had received an approach from NMC regarding a possible offer.

NMC said on Monday: "After a thorough assessment of the opportunity, NMC has concluded that the potential transaction would not deliver sufficient returns or shareholder value in line with its stated policy, and accordingly NMC now confirms that it does not intend to make an offer for Al Noor."

Last month, the boards of Al Noor and Mediclinic reached an agreement on the terms of a possible merger.

Under the proposed deal announced, Al Noor will acquire Mediclinic, with shareholders receiving 0.625 new shares for each Mediclinic share held.

The proposed deal will result in Mediclinic shareholders owning 84% to 93% of the enlarged group.

The groups said the merger will create a "leading international private healthcare group with deep operational expertise and a well-balanced geographic profile in Southern Africa, Switzerland and the United Arab Emirates".

At 1450 GMT, NMC Health shares were up 1.9% to 773.50p, while Al Noor was flat at 1,158p

Company News

NMC Health focuses on organic expansion after ditching Al Noor bid

Thu, 19 November 2015


NMC Health focuses on organic expansion after ditching Al Noor bid
(ShareCast News) - Emirates-based healthcare provider NMC Health reiterated its commitment to expanding capacity in the UAE and elsewhere, having announced earlier in the week that it had abandoned its bid for Al Noor Hospitals.
NMC said on Monday that after a thorough assessment of the opportunity, it had concluded that the potential transaction with Al Noor "would not deliver sufficient returns or shareholder value in line with its stated policy".

On Thursday, it looked as though the company was putting all that behind it.

The group said it has reviewed and assessed multiple proposed inorganic, organic and partnership opportunities over the past year and continues to be highly selective and disciplined in its investment process.

Deputy chief executive Prasanth Manghat said: "Over the past year we continued to execute our updated strategy in a highly dedicated and methodical manner with full focus on meeting our strategic objectives and delivering sustainable long-term growth, strategic and competitive advantages and shareholder returns.

"We look to the future and continue to see very favourable healthcare market dynamics and substantial growth opportunities for NMC Health in the UAE and the wider region."

NMC said it has completed four strategic and value-accretive acquisitions in the year to date, including fertility treatment company Clinica Eugin, ventilated care provider ProVita, homecare services provider Americare and UAE-based primary care provider Dr. Sunny Network.

The company expects to have 885 licensed beds available by the end of this year and a network of medical centres and day surgeries.

At 1430 GMT, NMC shares were down 0.4% at 764p.

Acquisition
RNS
RNS Number : 7427G
NMC Health Plc
24 November 2015



24 November 2015 - NMC Health plc expands its Maternity & Fertility vertical through the acquisition of a majority stake in Fakih IVF

NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated healthcare provider operating across the United Arab Emirates, is pleased to announce that it has entered into an agreement to acquire a 51% shareholding in Fakih IVF Group ('Fakih IVF') for AED696m (US$189 m). NMC has also agreed a mechanism by which it could increase its stake in Fakih IVF over time, based on certain conditions being met. Based on unaudited management accounts, Fakih IVF generated an EBITDA of US$25m for the nine months ended 30 September 2015, an increase of 20% year-on-year (YoY).

Fakih IVF, which comprises of Fakih IVF LLC and Fakih IVF Fertility Center LLC, is the Middle East market leader for in-vitro fertilisation (IVF) services, performing over 4,000 IVF cycles per annum and offering the only full service genetics laboratory in the region. Fakih IVF currently operates centres in both Abu Dhabi and Dubai and is looking to expand its footprint within the UAE as well as in the Gulf Cooperation Council (GCC) region. Fakih IVF is expected to open three additional UAE centres during 2016 in Al Ain city, Western region of Abu Dhabi Emirate and Sharjah. Fakih IVF has also achieved considerable progress in its regional expansion plan with IVF centres expected in both Qatar and Oman before year end 2016.

The transaction is aligned with NMC's Group strategy of establishing the company as a top in-class integrated provider of specialist care across its existing multi-brand and multi-segment healthcare verticals. This acquisition confirms the NMC Maternity & Fertility vertical's global market position, as one of the leading international providers of fertility treatment services based on;

§ Scale of its global business and cycle capacity

§ Focused strategic initiative towards raising capabilities and access to care in high growth and under-supplied markets

§ Segment leading treatment capabilities and success rates

§ Diversity and complexity of service offering across the fertility treatment spectrum

§ Established presence and referral centres across regulatory geographies to facilitate one-stop approach for patients

NMC Maternity & Fertility vertical now includes:

§ Brightpoint Royal Women's Hospital - Most advanced women's and maternity care hospital in the Middle East

§ Clinica Eugin - Top global fertility care provider based in Europe

§ Fakih IVF (51%) - UAE based Middle Eastern leader with the only full service genetics laboratory in the region

The combination with Fakih IVF is expected to be highly synergistic with significant potential for cross-referral of patients and transfer of best practices and technologies within NMC's Maternity & Fertility vertical. Patients will have access to an integrated continuum of care with complementing capabilities and coordinated seamless service offering including local IVF treatments of the highest international standards at Fakih IVF, international referral to Clinica Eugin and its wider fertility service offering as permitted by its operational and regulatory environment and NMC's hospitals, led by Brightpoint, for antenatal, delivery and postnatal services.

Furthermore, this transaction will increase the company's penetration into the Thiqa insurance segment, which is exclusively comprised of UAE nationals in Abu Dhabi, where fertility treatment is covered.

In addition, fertility treatments are one of the leading drivers of medical tourism in the UAE and the acquisition of Fakih IVF will position NMC as the destination of choice for fertility treatments with a complete service offering delivered by Fakih IVF and Clinica Eugin.

Over 50% of patients treated by Fakih IVF in Dubai are expatriates with over 25% being medical tourists. Approximately 80% of patients treated by Fakih IVF in Abu Dhabi are Emirati nationals covered by Thiqa insurance.

Dr. Michael Fakih, the founder and 100% beneficial owner of Fakih IVF, will remain as a 49% shareholder and Managing Partner in the business, thereby ensuring a smooth transition and limiting any potential integration risk. Dr. Fakih is also a renowned research professional with over a hundred international publications. He has been instrumental in his professional career for over 20,000 births from infertile couples using only IVF.

Dr. B.R. Shetty, Chief Executive Officer at NMC Health, commented:

"Our acquisition of a major shareholding in Fakih IVF is the logical next step towards achieving NMC's goal of becoming a global leader in maternity and fertility services. We are particularly excited about growing our in vitro fertilisation service offering within the UAE and look forward to further expand its geographic reach."

Information on Fakih IVF

Fakih IVF Group was founded in Dubai in 2011 by Dr. Michael Fakih, who has been established as a leading IVF physician in the USA and the UAE for over 20 years. The business expanded into Abu Dhabi in 2013 and currently performs over 4,000 IVF cycles per annum in the UAE. Fakih IVF offers a wide range of IVF-related services including intra-cytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), genetic testing, minimal stimulation IVF and male infertility treatments.

The business has one of the highest success rates for IVF services in the country and is the only IVF centre in the Middle East with an in-house Genetics Laboratory performing genetics screening for couples, embryos and also for the advanced personalised medicine. Fakih IVF was also the first to introduce the EmbryoScope in the UAE, a ground-breaking technology in the field of reproductive medicine and was the first centre in the UAE to perform a MicroTESE, a procedure that allows for sperm to be found even if sperm retrievals done earlier did not produce viable sperm for IVF.

Fakih IVF generated a net profit of US$16.6m and had gross assets of US$17.6m and net assets of US$13.7m in the financial year ended 31 March 2014.

Fakih IVF is expected to have a net cash position on its balance sheet at the time of closing.

Website: fakihivf.com

Financing and Financial Impact on NMC

The transaction will be financed using existing cash and credit facilities. NMC expects to retain, post transaction, a net debt to EBITDA level allowing the company financial flexibility for future growth initiatives.

Excluding synergies, the transaction is expected to be significantly accretive to NMC's EPS in 2016 with an attractive ROIC in excess of NMC's cost of capital.

Additional Information on the Transaction

The transaction is subject to customary terms and conditions. NMC expects the transaction to complete by the end of Q1 2016.

Evercore and FGB are acting as Financial Advisors to NMC. In addition, NMC is being advised by Allen & Overy, Clyde & Co. and PwC.

share-week-nmc-great-financial-health

18 Dec Jefferies... 1,350.00 Buy

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 954.53. Over this period, the share price is up 88.08%.

7 Mar Jefferies... 1,350.00 Buy

NMC Royal Hospital Officially Opened
RNS
RNS Number : 3261R
NMC Health Plc
08 March 2016

8 March 2016



NMC ROYAL HOSPITAL, UAE'S LARGEST PRIVATE HEALTHCARE FACILITY OFFICIALLY OPENED



NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated private healthcare provider operating across the United Arab Emirates ('UAE') and one of the top global providers of fertility treatments through its Spanish subsidiary Clinica Eugin, is pleased to announce the official opening of NMC Royal, its newest super speciality hospital, located in the Khalifa area of Abu Dhabi City.



The hospital is now providing inpatient services in addition to outpatient services begun in September 2015.



His Excellency Sheikh Nahayan Mubarak al Nahayan, the Honourable Minister of Culture and Knowledge Development inaugurated the official opening ceremony, which was attended by over 800 dignitaries, medical professionals and media. The delegates were given a tour of the 75,000 square-metre hospital, which has a licensed capacity of 250 beds with the potential to expand to 500 beds within the same premises.



Quartenery care multi specialty hospital



In addition to emergency care and critical care, NMC Royal's comprehensive specialties include neurosciences, cardiac sciences, gastroenterology, hepatology, urology, oncology as well as maternal & child health. A new nephrology unit, in addition to providing dialysis services, will also pioneer the private sector's kidney transplant programs.



NMC Royal's cutting edge technology includes a fully automated laboratory track system that can process up to 25,000 samples a day and over 200 different tests can be done in a single workflow. This computerized robotic system with minimal or no human intervention, significantly reduces turnaround times for doctors and patients and more importantly reduces error rates and risks of cross contamination. NMC Royal Hospital's radiology unit houses a 3 Tesla MRI Unit, whose magnetic field is twice the strength of many standard MRI units, making way for improved imaging and swifter diagnoses - a definitive benefit to neurosurgeons.



NMC's recent acquisition of Europe's leading fertility services provider Eugin and a majority stake in the GCC reproductive services leader Fakih IVF will also provide the latest technological expertise enabling the NMC Royal to set up a full-fledged In Vitro Fertilisation clinic and advanced capabilities for genetic disorders screening.



This capability will also be supported by the integration of wider clinical experience from recent acquisitions such as ProVita's long term acute care and Americare homecare expertise.



NMC Royal services the residents of Khalifa City, Al Raha, Mohammed bin Zayed City, Masdar City, Abu Dhabi International Airport, Shahama and Yas Island suburbs, which according to the Abu Dhabi Economic Vision 2030, are expected to house around one-fifth of the emirate's total population by 2030.



Dr. B.R. Shetty, Executive Vice-Chairman and Chief Executive Officer of NMC Health, commented:



"The opening of our new super speciality hospital, NMC Royal, not only brings long-awaited state-of-the-art medical services, healthcare facilities and emergency care to the residents of Abu Dhabi and the UAE at large, but its medical staff are trained in best global healthcare practices delivering quality healthcare. Central to our hub-and-spoke healthcare platform, NMC Royal will be a regional referral point for best-in-class medical treatment to the growing population of the UAE and NMC's rapidly growing patient population.



"NMC Royal signifies an important step in our strategy. As the largest private healthcare provider in the country with a combined licensed capacity of 885 beds across our integrated healthcare network, we remain uniquely well positioned to leverage our significant clinical expertise, enhanced by recent acquisitions, to deliver sustainable long-term growth and ultimately, shareholder returns."





- ENDS -

Final Results Mon 14 March

Final Results

FY2015 Financial Highlights



· Group reported revenues increased by 36.8% to US$880.9m. Proforma revenues increased by 45.8% to US$938.7m

· Healthcare division revenue increased by 55.7% to US$517.1m1. Proforma healthcare revenues increased by 73.1% to US$575.0m

· Distribution division revenue grew by 16.1% to US$393.4m2

· Reported EBITDA increased by 46.7% to US$150.3m. Proforma EBITDA increased by 61.2% to US$165.2m

· Reported EBITDA margin expanded by 116bps to 17.1%. Proforma EBITDA margins improved by 169bps to 17.6%

· Net profit increased by 10.6% to US$85.8m. Proforma net profit increased by 27.4% to US$98.8m

· Net profit margin declined by 230bps to 9.7% as a result of the accelerated ramp up of new openings leading to higher depreciation as well as the acquisition related amortisations. Proforma net profit margin decreased by 152bps to 10.5%

· Adjusted net profit increased by 21.2% to US$93.9m. Proforma adjusted net profit increased by 42.5% to US$110.5m

· Earnings per share (EPS) amounted to US$0.443 (FY 2014: US$0.412)

· Adjusted earnings per share amounted to US$0.506 (FY 2014: US$0.412)

· Proposed dividend pay-out ratio is maintained at 20% of profit after tax, amounting to GBP3 6.2 pence per share

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 985.00. Over this period, the share price is up 51.38%.

Broker Forecast - Investec issues a broker note on NMC Health PLC

Investec today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 1460p (from 1025p). Story provided by StockMarketWire.com

Ex divi 19 May 2016 NMC Health PLC (6.2 P)

Half year report

NMCenters Saudi Arabian market

30 Aug Jefferies... 1,570.00 Buy
30 Aug Numis N/A Buy

08:50 13/09/2016
Broker Forecast - Jefferies International issues a broker note on NMC Health PLC

Jefferies International today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 1625p (from 1570p). Story provided by StockMarketWire.com

Director Deals - NMC Health PLC (NMC)
BFN
Jonathan Bomford, Non Executive Director, bought 3,000 shares in the company on the 24th October 2016 at a price of 1499.14p. The Director now holds 15,000 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Acquisition
RNS
RNS Number : 8024R
NMC Health Plc
14 December 2016
 
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION as defined in Article 7 of the Market Abuse Regulation No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations
 
14 December 2016
 
NMC Health plc
(the "Company" or "NMC")
 
Proposed acquisition of the Al Zahra Hospital for AED 2,058 million (approximately US$560 million)
 
Strategic, accretive acquisition adds one of the largest private hospitals in the UAE and helps accelerate NMC's presence in the growing Sharjah healthcare market
 
·     NMC Health plc (LSE:NMC), the leading integrated healthcare provider operating across the United Arab Emirates (the "UAE"), is pleased to announce the proposed acquisition (the "Acquisition"), subject to certain conditions and approvals, of Al Zahra Hospital in Sharjah (the "Al Zahra Hospital") from Gulf Medical Projects Company ("GMPC") for AED 2,058 million (approximately US$560 million).
 
·     The Al Zahra Hospital is one of the largest private hospitals in the UAE, operating 137 active inpatient beds, serving approximately 400,000 outpatients and 23,000 inpatient bed days per year.
 
·     The Acquisition complements the NMC group's (the "Group") existing network of seven out-patient medical centres in Sharjah, the third most populated emirate in the UAE, to further strengthen the Group's position as the largest private healthcare provider in the UAE and in the Gulf Cooperation Council (the "GCC") region.
 
·     The Al Zahra Hospital has demonstrated a strong track record of growth and for the year ended December 2015 achieved revenue, EBITDA and net profit of US$130.4 million, US$43.5 million and US$38.8 million respectively.
 
·     The Directors of NMC (the "Directors") have identified approximately US$6.5 million of annual cost synergy benefits from the second year post completion of the Acquisition onwards. In addition to these initial cost synergy benefits, the Directors believe that there are a number of other operational and synergistic benefits that will accrue over the medium term.
 
·     In recent years, GMPC has invested significantly in the Al Zahra Hospital, including the addition of a new 17 storey block and three new operating theatres at a cost of US$33 million. The Directors believe that the recent investment in the 17 storey block will drive revenue growth over the medium and longer term as the additional added capacity drives increased patient numbers. In the future, the Directors believe that the Al Zahra Hospital has the ability to expand its capacity to approximately 200 beds with limited incremental investment required.
 
·     The Acquisition is conditional, inter alia, on shareholder approval.  As part of the financing of the Acquisition, the Company is undertaking a Placing of up to 9.99 per cent. of the issued share capital of the Company, as separately announced, and has also put in place new debt facilities.
 
·     The Company has continued to see positive trading since its interim results announcement. The Directors reiterate the Company's standalone 2016 EBITDA guidance of approximately US$240 million.
 
 
Prasanth Manghat, Deputy Chief Executive Officer of NMC, commented:
 
"The acquisition of one of the leading and most reputable hospitals in Sharjah carries tremendous strategic significance for NMC and expands the Group's reach within the region through our top-in-class offering, track-record and brand. This attractive and complementary deal is expected to deliver significant benefits for patients, as well as attractive synergies and be accretive for NMC shareholders in the first full year."
 
Dr. B.R. Shetty, Chief Executive Officer of NMC, commented:
 
"I am pleased to announce this strategic expansion into the attractive Sharjah healthcare market. This represents another major advance towards our objective of developing a leading integrated private healthcare operator in the UAE. These investments are fully in line with our strategy and demonstrate our focus on delivering long-term growth of our strategic and competitive capabilities to expand sustainable shareholder returns."

Proposed Placing of New Ordinary Shares
RNS
RNS Number : 8017R
NMC Health Plc
14 December 2016
 
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION as defined in Article 7 of the Market Abuse Regulation No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.
 
14 December 2016
 
NMC Health plc
(the "Company" or "NMC")
 
Proposed Placing of New Ordinary Shares to fund Acquisition
 
Introduction
 
NMC Health plc, the leading integrated healthcare provider operating across the United Arab Emirates ("UAE"), today announces its intention to place 18,571,428 new ordinary shares (the "Placing Shares"), representing approximately 9.99% of the current issued ordinary share capital of the Company (the "Placing").
 
The Placing is being conducted through an accelerated bookbuild (the "Bookbuild") which will be launched immediately following this Announcement, in accordance with the terms and conditions set out in the Appendix and will be made available to new and existing eligible institutional investors. HSBC Bank plc ("HSBC") and J.P. Morgan Securities plc (which conducts its UK investment banking activities as J.P. Morgan Cazenove) ("J.P. Morgan Cazenove" and together with HSBC, the "Bookrunners"), joint corporate brokers to the Company, are acting as joint bookrunners in connection with the Placing.
 
The Company's three largest shareholders, who together control approximately 61.6 per cent. of the Company's issued share capital (1), have provided letters of intent indicating their intention to subscribe for up to US$170 million / GBP134 million (2) (or their pro-rata if lower) of the Placing. The Placing is conditional on the participation of these shareholders. Should the Placing be oversubscribed, each of the three largest shareholders' participation may be reduced.
  
1.        Dr. B. R. Shetty controls approximately 25.7 per cent. of the Company's issued share capital while H. E. Saeed Bin Butti and Khalifa Bin Butti (directly and through Infinite Investment LLC) control in aggregate approximately 35.9 per cent of the Company's issued share capital
2.     Based on a GBP/USD exchange rate of 1.27, as at 13 December 2016
 
Background to the Placing and Use of Proceeds
 
The Company has separately announced today that is has agreed terms with Gulf Medical Projects Company ("GMPC") for the acquisition, subject to certain conditions and approvals, of GMPC's Al Zahra Hospital in Sharjah (the "Al Zahra Hospital"), comprising: the share capital of the Al Zahra (Pvt.) Hospital Company Limited and certain land and buildings currently used by Al Zahra Hospital, for AED 2,058 million (approximately US$560 million).
 
The Directors believe that the acquisition of the Al Zahra Hospital (the "Acquisition") is a unique opportunity to accelerate the delivery of its updated Healthcare Division strategy.
 
The Al Zahra Hospital complements the NMC group's (the "Group") existing network of seven out-patient medical centres in Sharjah, the third most populated emirate in the UAE, with one of the leading and most reputable hospitals in the emirate, to further strengthen the Group's position as the largest private healthcare provider in the UAE and one of the largest in the Gulf Cooperation Council (the "GCC") region.
 
Due to its size, the Acquisition constitutes a Class 1 transaction under the UK Listing Rules and the Company is therefore seeking the approval of the Shareholders for the Acquisition. Further details of the Acquisition and the transactions related to the Acquisition, together with a notice convening a General Meeting to consider the Acquisition, will be contained in the Shareholder Circular. The General Meeting will be convened in due course at which the Shareholders will be asked to consider, and if thought fit, pass a resolution to approve the Acquisition.
 
The Placing is not conditional on the completion of the Acquisition announced by NMC this morning. If the Acquisition does not complete, NMC will retain the net proceeds of the Placing for other potential acquisition opportunities.
 
The net proceeds of the Placing are intended to be used to part fund the Acquisition. The balance of the consideration, along with the repayment of the Company's current debt facilities, will be funded from new loan facilities of US$1.4 billion provided by J.P. Morgan Limited and Standard Chartered Bank, acting through its Dubai International Financial Centre (DFIC) branch. The new loan facilities provided by J.P. Morgan Limited and Standard Chartered Bank includes an 18 month bridge facility ("Facility C") which is not expected to be drawn as it will be replaced by part of the expected proceeds from the Placing.
 
Further information on the Acquisition and current trading can be found in the Acquisition announcement released by NMC today.
 
Details of the Placing
 
Under the terms of the Placing, the Company intends to place 18,571,428 new ordinary shares of 10 pence each in the capital of the Company, with both existing shareholders and new institutional investors. Members of the public are not entitled to participate in the Placing. The Placing is subject to the terms and conditions set out in the Appendix (which forms part of this announcement, such announcement and the Appendix together being the "Announcement").
 
The placing has been underwritten by the Bookrunners subject to the conditions set out in the placing and sponsor's agreement between the Company and the Bookrunners (the "Placing Agreement"). The Placing is conditional on the participation of the three major shareholders. A description of the Placing Agreement can be found in the Appendix to this Announcement.
 
The Placing is being conducted through an accelerated bookbuild process to be carried out by the Bookrunners. The book will open with immediate effect following this Announcement. The timing of the closing of the book, pricing and allocation are at the discretion of the Bookrunners. The Bookrunners may, in agreement with the Company, accept bids that are received after the Bookbuild has closed. The price per ordinary share at which such Placing Shares are to be placed will be announced on a Regulatory Information Service (the "Pricing Announcement") as soon as practicable after the close of the Bookbuild. 
 
Application will be made for the Placing Shares to be admitted to the premium listing segment of the Official List (the "Official List") of the Financial Conduct Authority (the "FCA") and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (the "London Stock Exchange") (together, "Admission"). Settlement for the Placing Shares and Admission is expected to take place on or before 8.00 a.m. on 16 December 2016. The Placing is conditional, amongst other things, upon Admission becoming effective and the Placing Agreement not being terminated. The Appendix sets out further information relating to the Bookbuild and the terms and conditions of the Placing. 
 
The Placing Shares, when issued, will be fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. The Company has agreed with the Bookrunners to a 90 day lock-up from Admission, subject to customary exceptions.
 
The Appendix sets out further information relating to the Bookbuild process and the terms and conditions of the Placing. Expressions used in this Announcement shall have the meanings set out in the Definitions section of the Appendix. By choosing to participate in the Placing and by making an oral and legally binding offer to acquire Placing Shares, investors will be deemed to have read and understood this Announcement in its entirety (including the Appendix) and to be making an offer on the terms and conditions and providing the representations, warranties, acknowledgements and undertakings contained in the Appendix. This Announcement should be read in its entirety. In particular, you should read and understand the information provided in the "Important Notices" section of this Announcement.

15 Dec
Jefferies...
1,825.00
Buy

Director Deals - NMC Health PLC (NMC)
BFN
Jonathan Bomford, Non Executive Director, bought 2,000 shares in the company on the 19th December 2016 at a price of 1499.64p. The Director now holds 17,000 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

21 Dec
Jefferies...
1,930.00
Buy

Full year results

FY2016 Financial Highlights
 
·        Group reported revenues increased by 38.6% to US$1,220.8m.
·        Healthcare division revenue increased by 59.2% to US$823.3m[1].
·        Distribution division revenue grew by 9.8% to US$431.9m[2]
·        Reported EBITDA increased by 63.7% to US$246.1m.
·        Reported EBITDA margin expanded by 309bps to 20.2%.
·        Net profit increased by 76.5% to US$151.4m.
·        Net profit margin increased by 267bps to 12.4%.
·        Adjusted net profit increased by 69.4% to US$165.2m.
·        Earnings per share (EPS) amounted to US$0.711 (FY 2015: US$0.443)
·        Adjusted earnings per share amounted to US$0.785 (FY 2015: US$0.506)
·        Proposed dividend pay-out ratio is maintained at 20% of profit after tax, amounting to GBP[3] 10.6 pence per share
 
FY2016 Business Highlights - A year on year (YOY) comparison
 
·        Healthcare division's patients increased by 34.5% to 4.3m.
·        Revenue per patient from healthcare services increased by 28.3% to reach US$176.3.
·        Hospital bed occupancy rates reached 74.3%, an improvement of 80bps.
·        Operational beds increased from 537 beds to 679 beds, 26.4% increase
·        Doctors' employed reached 1042, an increase of 27.5%
·        Distribution division increased its product portfolio by 9.3% to 97,600 stock keeping units (SKUs)
·        Sales and marketing personnel at the Distribution division grew 11.0% to 769

NMC Health AGM and Dividend Timetable
RNS
RNS Number : 1622D
NMC Health Plc
24 April 2017
 
NMC Health Plc - AGM and Dividend Timetable 
 
London, 24 April 2017: NMC Health Plc ("NMC" or the "Company") (LSE:NMC), the leading integrated private healthcare provider operating across the United Arab Emirates, announces circulation of its Notice of 2017 Annual General Meeting and confirms details of the timetable for payment of its 2016 final dividend.
 
The Company's 2017 Annual General Meeting will be held on Tuesday 23 May 2017, at 2:00 pm at the offices of Allen & Overy LLP, One Bishops Square, London E1 6AD. A copy of the Notice of 2016 Annual General Meeting Circular and the accompanying Form of Proxy have  been submitted to the National Storage Mechanism and are available for inspection at www.Morningstar.co.uk/uk/NSM.  In addition, the Circular is available to view on the Company's website http://www.nmchealth.com/shareholder-information.
 
Following the 2016 financial year preliminary results announcement of the Company made on 8 March 2017, in which the Board announced that it is recommending a final dividend of 10.6 pence per ordinary share, the Company hereby confirms the following timetable for payment of this dividend:
 
·     Ex-dividend date - 11 May 2017
 
·     Record date - 12 May 2017
 
·     Payment date - 2 June 2017
 
Payment of the final dividend remains subject to shareholder approval at the Company's 2017 Annual General Meeting.

Abu Dhabi regulatory and trading update
RNS
RNS Number : 8020D
NMC Health Plc
02 May 2017
 
2 May 2017
 
NMC Health plc
(the "Company" or "NMC")
 
Abu Dhabi regulatory announcement and trading update
 
 
NMC Health plc (LSE:NMC), the leading integrated healthcare provider operating across the United Arab Emirates notes the recent statements made by His Highness Sheik Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Commander of the UAE Armed Forces and subsequent confirmation by the Health Authority of Abu Dhabi ("HAAD") to NMC on 27 April 2017, regarding regulatory changes to Thiqa cardholders in Abu Dhabi, effective immediately:
 
·      The removal of the 20% co-payment on services accessed by Thiqa cardholders at private Abu Dhabi healthcare facilities;
 
·      Reduction in the co-payment for services accessed by Thiqa cardholders outside of the Emirate of Abu Dhabi from 50% to 10%; and
 
·      Removal of IVF related restrictions
 
As previously communicated, NMC's Long-term & Home Care vertical was exempt from the changes made to the co-payment on services.
 
NMC expects these changes to positively impact its entire healthcare portfolio.  In particular, NMC Royal Hospital, Al Zahra Hospital and Fakih IVF are anticipated to be key beneficiaries of the revised regulations. NMC now expects full year EBITDA to be towards the top end of the current guidance range of USD 335-350mn.

Ex divi 11 May 10.6p payment 2 June.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 2,180.00. Over this period, the share price is up 105.23%.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 2,337.00. Over this period, the share price is up 102.52%.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 2,739.00. Over this period, the share price is up 102.07%.

Tipped by the Telegraph over the weekend.

10:50 03/10/2017
Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
Jefferies International today reaffirms its hold investment rating on NMC Health PLC (LON:NMC) and raised its price target to 2810p (from 2450p). Story provided by StockMarketWire.com

6 Oct
Berenberg
4,000.00
Buy

Director Deals - NMC Health PLC (NMC)
BFN
Salma Hareb, Non Executive Director, bought 6,600 shares in the company on the 12th October 2017 at a price of 2970.98p. The Director now holds 6,600 shares representing 0.00% of the shares in issue.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Sharecast -Middle East hospital operator NMC Health was rising even higher after Deutsche Bank lifted its target price to 3,920p from 2,820p.

Acquisitions of outstanding minority interests
RNS
RNS Number : 9443A
NMC Health Plc
04 January 2018


4 January 2018

NMC Health plc
(the "Company" or "NMC")

Continued progress against group strategy

- Acquisition of minority stakes in Fakih IVF and As Salama Hospital
- Enterprise Values of both Fakih IVF and As Salama Hospital approximately the same as at the time of original acquisitions, despite substantial growth in underlying profitability
- Formal closing of Al Qadhi and Al Rashid Hospital transactions in KSA


NMC Health plc (LSE: NMC), the leading integrated healthcare provider operating across the United Arab Emirates, is pleased to announce that it has acquired the outstanding minority stakes in Fakih IVF and As Salama Hospital for a total consideration of c. USD 218mn, implying 2017 P/E multiple of just under 10x for the two assets combined. The Company also announces the completion of the previously announced Al Qadhi and Al Rashid Hospital transactions in the Kingdom of Saudi Arabia (KSA).

Acquisition of minority stakes in Fakih IVF and As Salama Hospital

NMC has acquired the outstanding 49% minority stake in Fakih IVF at approximately the same Enterprise Value as the original acquisition cost set in 2015. The acquisition is being settled in the form of cash and newly issued shares in NMC Health with a total consideration of USD 205mn (27% cash, 73% NMC shares issued, which represents c.3.5 million shares or 1.8% of NMC's current issued capital based on NMC's current share price of £29.20 ($39.42 at a GBPUSD exchange rate of 1.35 for 3 January 2018)). In addition, Dr. Michael Fakih will retain his role as a Medical Director in NMC and continue his practice as a medical doctor.

With Fakih IVF now a wholly owned subsidiary of NMC, the Company is better positioned to accelerate and expand growth globally within its fertility business. NMC will continue to expand its fertility network, from the new IVF clinics opened in UAE and Oman in 2017 and additional expansions planned in other geographies, particularly KSA, to maintain a market leading position.

As owner of the remaining 49% stake in Fakih IVF being acquired, and as a director of Fakih IVF, which is a subsidiary undertaking of NMC, Dr. Fakih is therefore deemed to be a related party to NMC for the purposes of Listing Rule 11. The transaction amounts to a smaller related party transaction as defined in Listing Rule 11.1.10.

The outstanding 30% minority stake in As Salama Hospital was acquired at the same Enterprise Value of USD 45mn which was set in 2016 with the initial 70% stake. The acquisition is being fully settled in cash.

These two acquisitions were financed from the issuance of shares to Dr. Fakih and existing cash resources from our strong and stable balance sheet which remains within our leverage guidance. In aggregate Fakih IVF and As Salama Hospital would have contributed c. USD 22mn to NMC's FY17 net income on a pro forma basis. The acquisitions became effective on 1 January 2018.

Closing of Al Qadhi and Al Rashid Hospital purchases in KSA

As announced on 25 September 2017, NMC acquired a 60% stake in Al Qadhi Hospital in Najran and a 100% stake in Al Rashid Hospital in Ha'il for an aggregate consideration of USD 40m. All formalities related to both transactions have now been completed and the contributions from both hospitals will be consolidated in NMC's results from the beginning of 2018. These facilities represent an important step ahead in NMC's drive to establish a well-developed footprint in KSA.

Prasanth Manghat, Chief Executive Officer, commented:

"In December 2017, I set out our strategy to drive the Company's next phase of growth. The transactions today fit with our commitment to increase our capacity, capabilities and geographic coverage. The acquisition of the outstanding minority stakes in Fakih IVF and As Salama Hospital represent highly value accretive transactions for NMC's shareholders. In particular, the Fakih IVF transaction provides us with an enhanced platform from which to grow our fertility business. As the second largest global IVF player, NMC remains very well positioned to be the leading consolidator in the fertility market. We will continue to seek opportunities to consolidate minority stakes in our subsidiaries, as we increase our knowledge and understanding of these businesses, where we can create further value for shareholders."

Earnings accretive acquisitions in the UAE and KSA
RNS
RNS Number : 4630C
NMC Health Plc
22 January 2018

22 January 2018

NMC Health plc
(the "Company" or "NMC")

Earnings accretive acquisitions in the UAE and Kingdom of Saudi Arabia

NMC Health plc (LSE: NMC), the leading United Arab Emirates private healthcare operator with international services across 13 countries, is pleased to announce two acquisitions and the completion of new Operating and Management (O&M) contracts. These accretive transactions demonstrate further progress in-line with the Company's strategic priorities to expand capacity, capabilities and geographic reach.

- Acquisition of 70% stake in CosmeSurge and related businesses
· Transaction includes a chain of 17 operational clinics, enhancing NMC's Cosmetics services portfolio
· Purchase consideration of USD 170mn, translating into 10.6x 2018E EV/EBITDA
· High margin, double-digit growth business operating in an attractive market segment
· Expected to be earnings and margin accretive from first year of acquisition

- Increased capacity in KSA with acquisition of 80% stake in Riyadh-based Al Salam Medical Group
· Further extends NMC's foothold in KSA with a 100-bed hospital and 2 clinics in the attractive Riyadh market
· Purchase consideration translates into a blended 2018E EV/EBITDA multiple of less than 7x
· Initial consideration of c. USD 37mn payable upon closing and a deferred consideration to be paid after 1 year based on business's financial performance
· Expected to be earnings accretive from first year of acquisition

- New O&M contracts extend geographic reach into Egypt

Strengthening NMC's cosmetics and aesthetics platform

NMC has acquired a 70% stake in CosmeSurge, an industry leader in providing quality cosmetic surgery and aesthetic medicine, and related businesses, at an implied Enterprise Value of c. USD 250mn. The business is expected to deliver 2017 revenues and EBITDA of approximately USD 67mn and USD 20.5mn, respectively, representing an attractive 31% EBITDA margin. The consideration will be settled in cash and the transaction is expected to be completed during Q1 2018. Assets being acquired under the transaction include 17 operational clinics. Additionally, a 10-bed hospital and two new clinics are currently under construction in the UAE, which are scheduled for opening during H1 2018.

NMC currently provides invasive cosmetic procedures and complex surgeries and the addition of CosmeSurge will substantially enhance the Company's cosmetics and aesthetics offering. Having managed CosmeSurge and related businesses since September 2017 under an O&M contract, NMC has already identified a wide number of revenue and cost synergy opportunities. These include cross-referral of patients, reduced capex requirement from leveraging NMC's existing capacity and cost sharing of support services related to HR, IT and procurement.

CosmeSurge and related business have been acquired from Emirates Healthcare Group. Emirates Healthcare Group is majority controlled by KBBO Group, a consortium of private investors in Abu Dhabi with a portfolio of interests across a variety of sectors. The Chairman of KBBO is Khalifa Bin Butti, who is also the Executive Vice Chairman and a substantial shareholder of NMC. For the purposes of Listing Rule 11, he is a related party of NMC and the proposed transaction constitutes a related party transaction. The transaction amounts to a smaller related party transaction as defined in Listing Rule 11.1.10.

Al Salam Medical Group extends KSA footprint

NMC has acquired an 80% stake in Al Salam Medical Group, a healthcare company in Riyadh, the largest healthcare market in KSA. The transaction is expected to be completed in H1 2018 and includes the 100-bed Al Salam Medical Hospital (commissioned in Q4 2016), the Al Salam Medical Center (established in 1985) and the Ishbilia Medical Center (established in 2003).

Al Salam Medical Group's hospital and clinics focus on a number of key specialties, including cardiology and pediatrics. NMC also sees an opportunity to add substantial value to the acquired assets by introducing further specialties and sharing best practices. As such, NMC plans to add long-term care, cosmetics and IVF services, post the completion of the acquisition.

New O&M contracts expand footprint into Egypt

NMC has also signed new Operations & Management (O&M) contracts with Emirates Healthcare Group to manage its Egyptian hospitals, Dar El Fouad and As Salam International, which have a combined capacity of 860 beds. The contract will generate revenues of USD 2mn for NMC in the first year of operation. Previous guidance for 2018E revenues for the O&M vertical is therefore maintained at USD 19mn as the new contract replaces the anticipated reduction in O&M revenues due to acquisition of CosmeSurge and related businesses.

Prasanth Manghat, Chief Executive Officer, commented:

"These value accretive and earnings enhancing transactions fit well with our growth strategy. CosmeSurge represents a continuation of building NMC's capabilities and Al Salam further extends our geographic footprint in the KSA, cementing our leading position as a non-domiciled provider. We see substantial opportunities for revenue and cost synergies across both acquisitions, and the Cosmetics business in particular has the potential to be further developed into an independent business vertical at a later stage. Moreover, KSA remains a key focus market for us and despite already reaching 800 beds across existing and under-construction assets in the country, we continue to see strong growth opportunities in the Kingdom."

Completion of Fakih IVF acquisition
RNS
RNS Number : 1275D
NMC Health Plc
29 January 2018

NMC Health plc

Completion of Fakih IVF acquisition
Share Listing Application
Total Voting Rights


London, 29 January 2018: NMC Health plc (LSE: NMC), the leading United Arab Emirates private healthcare operator with international services across 13 countries announces that the acquisition of the outstanding 49% minority stake in Fakih IVF (the "Acquisition"), announced on 4 January 2018, formally completed on 28 January 2018.

As part consideration for the Acquisition, a total of 3,533,857 new ordinary shares of 10 pence each fully paid in the Company (the "Consideration Shares"), have been issued by the Company. Application has been made to the UK Listing Authority for the admission to the Official List of the Consideration Shares and to the London Stock Exchange for such shares to be admitted to trading. These shares will rank pari passu in all respects with the existing ordinary shares of the Company.

Admission of the shares to the Official List is expected to occur on 30 January 2018.

As at 29 January 2018, NMC Health plc's issued share capital consists of 207,957,709 Ordinary Shares of 10p each, with each share having one voting right attached. No shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, NMC Health plc under the FCA's Disclosure and Transparency Rules.

29 Jan
Berenberg
4,000.00
Buy

Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
BFN
Barclays Capital today initiates coverage of NMC Health PLC (LON:NMC) with a overweight investment rating and price target of 4100p.

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.u

06/02/2018
BUY
Lord Clanwilliam
NED
3,000

Final results

FY2017 Financial Highlights

· Group reported revenues increased by 31.3% to US$1,603.4m.
o Organic growth accounted for 15.6% YoY increase in revenues
· Healthcare division revenue increased by 41.1% to US$1,161.6m1.
o Healthcare EBITDA margin stood at 31%, up 130 bps YoY
· Distribution division revenue grew by 12.7% to US$486.8m2
o Distribution EBITDA margin declined slightly to 10.6%
· Reported EBITDA increased by 43.6% to US$353.4m.
· Reported EBITDA margin expanded by 180bps to 22.0%.
· Net profit increased by 38.2% to US$209.2m.
· Net profit margin increased by 60bps to 13.0%.
· Adjusted net profit increased by 43.2% to US$236.6m.
· Earnings per share (EPS) amounted to US$0.910 (FY 2016: US$0.711)
· Adjusted earnings per share amounted to US$1.036 (FY 2016: US$0.781)
· Proposed dividend pay-out ratio is maintained at 20% of profit after tax, amounting to GBP3 13 pence per share

FY2017 Business Highlights - A year on year (YOY) comparison
· Healthcare division's patients increased by 33.5% to 5.8.m.
· Revenue per patient from healthcare services increased by 7.6% to reach US$189.8
· Hospital bed occupancy rates reached 71.6%, a decrease of 270bps.
· Operational beds increased from 679 beds to 1365 beds, 101% increase
· Doctors' employed reached 1437, an increase of 37.9%
· Distribution division increased its product portfolio by 17.5% to 108,900 stock keeping units (SKUs)
· Sales and marketing personnel at the Distribution division grew 6.6% to 820

13:00 23/03/2018
Broker Forecast - Berenberg issues a broker note on NMC Health PLC
Berenberg today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 4000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

New high.

Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
BFN
Jefferies International today reaffirms its hold investment rating on NMC Health PLC (LON:NMC) and raised its price target to 3291p (from 3085p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

Agreement
RNS
RNS Number : 8587Q
NMC Health Plc
11 June 2018

11 June 2018

NMC Health plc
(the "Company" or "NMC")

NMC enters into a transformational partnership with Hassana Investment Company to create a new healthcare platform in Kingdom of Saudi Arabia


NMC Health plc (LSE: NMC), the leading United Arab Emirates private healthcare operator with international operations across 13 countries, is pleased to announce the signing of a non-binding agreement to form a joint-venture healthcare platform with Hassana Investment Company ("Hassana"), the investment arm of the General Organization for Social Insurance ("GOSI"), which is the largest pension fund in Kingdom of Saudi Arabia ("KSA").

· Proposed formation of a new national healthcare company, pursuing a unique strategy in KSA
· JV to be formed through contribution of existing assets by both NMC and GOSI's investment in Tadawul-listed National Medical Care Company ("CARE")
· At inception, the platform would be one of the largest private healthcare operator in KSA by beds capacity
· NMC and Hassana have ambitious plans to expand and benefit from the strong growth potential of the healthcare sector in KSA through the proposed entity
· GOSI would continue to own a significant indirect stake in CARE through this proposed JV
· The proposed partnership would drive NMC's strong expansion in the KSA healthcare market


Larger platform to deliver more efficient deployment of capital in KSA

The proposed JV would create one of the largest private healthcare platforms operating in KSA today. The JV would have a strategically unique position in the country, with a strong foothold in Riyadh, the single largest healthcare market in KSA, as well as in multiple smaller, underserved cities. The enlarged organization is expected to benefit from economies of scale, allowing more efficient deployment of capital, increasing patient choice and optimizing returns across multiple assets. Furthermore, in-line with NMC's existing strategy, the proposed JV platform would continue to build a strong pan-KSA presence, unlocking considerable synergies across its facilities in the process. These are expected to cover business segments such as revenue cycle management, procurement, HR and IT systems among others.

Key terms of the agreement

· GoSI/ Hassana will transfer their 38.9% stake in CARE at a price of SAR 70/share, implying an attractive 2018E EV/EBITDA multiple of less than 15x
· NMC will contribute all of its existing KSA-based assets as part of the formation of the JV platform
· Under the terms of the agreement, there will be revaluation of NMC's assets, representing considerable value accretion at the joint-venture as well as NMC Health plc level
· The JV will have a combined bed capacity of 1,489 (664 beds contributed by NMC and 825 by CARE)
· Formation of the JV is subject to regulatory approvals and signing of definitive agreements after completion of necessary due diligence by both the parties
· For the year ended 31 December 2017, NMC reported gross assets of US$3.0 billion and profits before tax of US$210.4 million. For the same period, CARE reported gross assets of US$380.0 million and profits before tax of US$26.7 million


NMC will retain a majority stake, as well as operational control, in the JV

NMC will hold a voting majority in the proposed JV, with the exact stake subject to final terms. Consequently, NMC will fully consolidate the JV financials. NMC will also retain operational and management control of the assets held by the JV.

The proposed JV platform will serve as the main vehicle of future expansion for NMC in KSA. The proposed JV will seek to take majority, as well as minority, stakes in KSA-based healthcare operators (organic and inorganic investments), along with acquiring O&M contracts to manage private and government sector hospitals in the country.

The JV platform is expected to benefit significantly from NMC's operational expertise in the healthcare sector, as well as Hassana's local market knowledge and strategic position as a long term financial investor. The formation of this platform represents the strong commitment by both NMC and Hassana towards the KSA healthcare market.

Prasanth Manghat, Chief Executive Officer of NMC, commented:

"We identified KSA as a key strategic priority for NMC and the proposed partnership between NMC and GoSI/ Hassana would offer a tremendous opportunity for both the companies to better serve the KSA healthcare market. The Saudi government's forward looking and investor friendly policies make the Kingdom one of the most attractive destinations in the region for investment in the healthcare sector. Moreover, Hassana's strong commitment to the sector, particularly in the form of strategic investments, remains a vital means of attracting and developing healthcare expertise in the country. NMC has been the most progressive foreign entrant in the Saudi healthcare market, and the proposed partnership with Hassana would accelerate the process of bringing international best practices to KSA. In addition to being ideally positioned to participate in the highly anticipated privatization program in KSA, the proposed JV platform will continue to fill service gaps in the market. This is expected to be achieved through a wide range of means, be it through the development of IVF, long-term care and cosmetics segments or the introduction of pediatric centers of excellence and state-of-the-art cancer centers."

Saad bin Abdulmohsen Al-Fadly, Chief Executive Officer of Hassana, commented:

"The proposed partnership between Hassana and NMC is driven by our view that healthcare in Saudi Arabia is one of the most attractive markets for strong long-term growth. The proposed JV has ambitious growth plans across different healthcare sub-sectors, with both partners committed to compounding returns over the long-term, whilst providing best-of-class services to patients. Benefiting from Hassana's role as a strong long term financial and strategic investor and NMC's expertise as a sophisticated and successful healthcare expert in the region, the JV platform would be well-positioned to become one of the most dominant healthcare players in Saudi Arabia and is ideally positioned to capitalize on the health care privatization program in Saudi Arabia in line with the country's Vision 2030 initiatives."

08:10 07/08/2018
Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
Barclays Capital today reaffirms its overweight investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 4250p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Business Update
RNS
RNS Number : 2230Y
NMC Health Plc
20 August 2018

20 August 2018

NMC Health plc
(the "Company" or "NMC")

Continuous execution of 2017 enhanced strategy

Further geographic expansion of the IVF platform: Extending foothold in Europe and entry into the African market

First O&M contract signed in sub-Saharan Africa

UK acquisition reinforces capability enhancement program

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces significant progress the Company has made during 2018 against the updated strategy announced in December 2017.

Development of Centers of Excellence as potential verticals

With the verticals-based structure serving NMC well across its rapid growth, the Company continues to evaluate potential new additions to the framework. As highlighted previously, the recently acquired cosmetics business represents a strong candidate in this regard. Additionally, NMC's Pediatric Centre of Excellence is rapidly emerging as a potential new, organically grown vertical. The Company has significantly enhanced the quality and complexity of pediatric care in the UAE following its collaboration with Cincinnati Children's Hospital, one of the top two children-focused hospitals in the US. Under the terms of the agreement, key child specialists from the American hospital visit NMC Royal hospital on a periodic basis, bringing previously unavailable medical services in the country. Given the shortage of pediatric healthcare services in the GCC in general and the UAE in particular, this segment represents strong potential for growth, and hence an upgrade to a vertical status.

While the abovementioned offer the nearest term potential to form new verticals, management continues to see promise across a number of other Centers of Excellence that could eventually become independent verticals as well. The most prominent among these include Orthopedics, Cardiology, Oncology and Ophthalmology.

Expanding healthcare business target market from GCC to wider Emerging Markets

NMC's Operations & Management (O&M) vertical continues to serve as a risk-controlled means of gaining exposure to new markets outside the GCC and evaluating opportunities for capital deployment. Following the Egyptian O&M contracts announced in January 2018, NMC has now extended its reach to sub-Saharan Africa through signing of O&M contracts with private parties in Kenya. Signed on 1 July 2018, the contracts cover two hospitals in Nairobi and will generate revenues of US$2m per annum. Additionally, the Kenyan government has requested NMC to advise on affordable healthcare technology for school going students.

In addition to high margin revenues, the O&M contracts are expected to provide considerable cross referral opportunities to NMC's UAE-based facilities. Kenya, as well as the wider sub-Saharan Africa, remains an important source of medical tourism to the UAE due to its geographic proximity and conducive visa regulations.

Extending the IVF global footprint

Highlighted during the 2017 strategy update as a truly global opportunity, NMC's IVF business continues to extend its international reach, with three new markets added recently including Sweden, Latvia and Kenya. The Company has acquired leading IVF clinics in Sweden and Latvia, broadening its foothold in the attractive European market for a combined consideration of c. US $25m. In addition to being value accretive acquisitions (both transactions completed at multiples below 8x 2018E EV/EBITDA), these top-rated clinics add substantial research expertise in the Fertility segment. They also bring highly experienced doctors to NMC's team, including world renowned gynecologist, Dr. Mats Brännström, who made history by successfully conducting the world's first uterus transplant.

Moreover, adding a fourth continent in the form of Africa, NMC's Fertility business has entered the Kenyan market through a Greenfield expansion in Nairobi. Fully integrated with our European brand, Clinica Eugin, the clinic will be the only global platform in Africa. Infertility represents a major reproductive health problem across Africa in general and in sub-Saharan Africa in particular. Given its solid expertise in Europe, in-house resources, operational expertise and research capabilities, NMC is ideally positioned to invest in this developing market. With the Kenyan facility expected to attract patients from adjoining East African markets of Tanzania, Uganda and Rwanda, NMC views its state-of-the-art clinic as a launchpad for the attractive African market.

Acquisition of UK-based Aspen Healthcare: Establishing Centers of Excellence in GCC with capability enhancement program

NMC has acquired 100% of the equity of Aspen Healthcare ("Aspen") from Tenet Healthcare for an Enterprise Value of GBP 10m. Aspen operates a network of nine facilities across the UK including four hospitals, three of which are based in Greater London (Parkside Hospital, The Holly Private Hospital and Highgate Hospital).

Aspen facilities provide quality services, with NHS accounting for less than 30% of revenues. While offering a large range of specialties, Aspen is particularly recognized in Orthopedics and Oncology, which represent 50% of the company's revenues. Both segments remain highly underserved in the UAE, thus offering the dual benefit of knowledge transfer as well as potential for patient referral to NMC's own international facilities when the required medical treatment is unavailable in the country.

The acquisition also provides NMC a very cost-effective means of introducing its fertility services to the UK. Situated in prime locations, the facilities have the required civil structures in place for rapid deployment of our world-renowned IVF services.

NMC's management sees significant opportunity for driving margin and earnings growth at the newly acquired facilities. However, while capital expenditure is planned for the Aspen facilities, NMC does not currently intend to invest in other non-fertility based healthcare facilities in the UK.

NMC intends to finance the transaction using existing cash resources. For the year ended 31 December 2017, Aspen reported EBITDA of £5m (US$7m) and had gross assets of £173m (US$221m). The transaction is expected to be neutral to NMC's EPS in 2018.

Adapting to rapid technological developments in the healthcare sector

NMC is ardently keeping an eye on global digital health trends, such as mobile health, artificial intelligence enabled healthcare platforms, genomics and robotics. These developments are expected to have a dramatic impact on healthcare delivery in the coming years. NMC is exploring novel ways to collaborate with industry leaders in these technological fields to pioneer a futuristic healthcare value chain to improve accessibility, enhancing clinical outcomes and reducing costs.

Mr Prasanth Manghat, Chief Executive Officer, commented:

"In December 2017, we set out our new strategy to drive future growth by focusing on leveraging our healthcare services expertise to increase capacity, growing our capabilities and expanding across multiple geographies. Our flexible model allows us to consider opportunities to manage as well as own healthcare facilities. We continue to expand into new geographies, with our footprint now spread across 17 countries. Despite the passage of a relatively short time period since outlining the enhanced strategy, we have made substantial progress across all facets. We continue to strengthen NMC's reputation as a provider of world class services for our patients and are cementing our position as a leading global healthcare operator."

Half year report part1

H1 2018 Group financial highlights

· Group reported revenues increased by 20.2% YoY to US$932.0m, with organic growth accounting for 13.4% of this growth
· EBITDA margin increased by 220bps to 24.2% as EBITDA growth (+32.1% to US$225.5m) continues to outpace revenue growth
· Financial and operational performance during H1 2018 remained in line with expectations, with management maintaining positive outlook for H2 2018

Half year report part2

Broker Forecast - JP Morgan Cazenove issues a broker note on NMC Health PLC
BFN
JP Morgan Cazenove today reaffirms its neutral investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4060p (from 3270p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

10:00 22/08/2018
Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
Barclays Capital today reaffirms its top pick investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4850p (from 4600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

21 Sep
Barclays...
N/A
Overweight
22 Aug
Barclays...
4,850.00
Top pick

i hold a few of these in my sipp, and thus with a fairly long term view
it's certainly a dangerous stock to try to trade as the chart shows, for it can be horribly volatile for no apparent reason

There was another UAE hospital/ health care provider I opened a thread for at the same time. I think they changed the company name, but this one has out performed it. Yes can be volatile.

Mediclinic International Plc (MDC) found it.

Not sure you will have heard of this company dream , but it has promise , it's called Versarien , AGM on Tues 25th , keep it to yourself as it could rocket soon .

Who are they? I hope you filled your boots on the normal pullback.

Suppose I should have learnt that by now , I'll have to get into this profit taking mentality , see it's on it's way back up now , it's the fear of news coming pre agm .

Playing with all profit only now, Which we all must have a very good balance. :-))

Going to be an interesting afternoon. Hold your hats on.lol

Capital Markets Day & Positively Revised Guidance
RNS
RNS Number : 6831E
NMC Health Plc
22 October 2018

22 October 2018

NMC Health plc
(the "Company" or "NMC")

Capital Markets Day and Positively Revised Guidance

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces that the Company will be holding a Capital Markets Day today at the London Stock Exchange.

Prashanth Shenoy, Chief Financial Officer of NMC Health, will provide an update on guidance given in January, following positive developments in the second half of 2018. As a result, we now anticipate an increase of 2% in revenue growth from 22% to 24% and an increased EBITDA guidance from $465m to $480m by year-end 2018.

2019 guidance will also point towards continuation of strong organic growth on the back of sustained ramp-up at key facilities, integration and expansion of acquired entities as well as strong operational performance. Revenues are forecast to increase by 22-24% and EBITDA is expected to increase by 18-20%. 2019 guidance does not include the effects of implementation of IFRS 16. The guidance also does not reflect the impact of anticipated financial consolidation of National Medical Care Company. An update in this regard will be provided once the joint-venture with Hassana/GOSI has been formalized, which is on track for completion during Q4 18.

During the year 2019, management also anticipates: 1) opening of new greenfield facilities, particularly in UAE, 2) continued ramp-up of various facilities across multiple geographies and 3) full-year consolidation of Aspen Healthcare, all of which will impact EBITDA margin.

Management remains confident on the longer-term margin guidance for the Company and NMC remains on track to achieve 25% EBITDA margin by 2020/2021.

10:00 23/10/2018
Broker Forecast - HSBC issues a broker note on NMC Health PLC
HSBC today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 1430p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Purchase of Shares
RNS
RNS Number : 8923F
NMC Health Plc
31 October 2018



NMC Health plc

Purchase of Shares


London, 31 October 2018: NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, received notification from Jonathan Bomford, the Senior Independent Director of the Company, that on 31 October 2018 he bought through his SIPP, 1,000 ordinary shares of 10p each in the Company ("Shares") at a price of 3475.545p pence per share.

Following this transaction, Jonathan Bomford's share interest, including the shares held by his spouse, has increased to 20,000 Shares, representing approximately 0.01% of the issued share capital of the Company.

a good healthcare company based in m/e, so not quite as susceptible to uk jitters
nevertheless, it can be quite volatile

have just topped up my sipp to an "average" holding

and a nice rise today of 6% perhaps on the back of an upgrade from jpm

Hopefully back above £40 :-))

09:50 27/11/2018
Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
Jefferies International today downgrades its investment rating on NMC Health PLC (LON:NMC) to underperform (from hold) and cut its price target to 2940p (from 3411p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Trading Update
RNS
RNS Number : 8932J
NMC Health Plc
10 December 2018

10 December 2018

NMC Health plc
(the "Company" or "NMC")

Trading Update: Reiterating 2018 & 2019 financial guidance; delivering further positive operational progress

Strong growth is underpinned by NMC's strategy of focusing on business segments well beyond multi-specialty, a wide geographic footprint in its target markets and offering healthcare for all segments

H2 cash flow improved as actions taken to normalize receivables continue to yield results

KPIs for management LTIP revised to better align with shareholder value creation

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, maintains its positive outlook for the remainder of 2018, as well as 2019.

Management remains comfortable with and reiterates guidance for 2018 and 2019

Given the combination of NMC's strategy, supportive underlying industry dynamics and continued positive operational developments, management remains comfortable with the financial guidance it provided for 2018 and 2019 at its recent Capital Markets Day. Of particular note is the continued roll out of insurance coverage in NMC's core markets, including the completion of the mandatory insurance program last year in Dubai. Guidance remains as follows:

FY 2018 Guidance:

- +24% YoY revenue growth
- Organic revenue growth approximately 15% for the year
- +36% YoY growth in EBITDA to USD 480m
- Year-end net-debt to EBITDA to stand at c. 3.0x

FY 2019 Guidance:

- +22-24% YoY revenue growth
- +18-20% YoY EBITDA growth
- Excluding impact of acquisitions completed in 2018, FY 2019 revenue growth is anticipated to be 12-13% YoY and EBITDA growth approximately 15% YoY
- Year-end net-debt to EBITDA to further reduce to 2.2-2.4x
- 2019 guidance does not include impact of IFRS 16 implementation or the anticipated consolidation of National Medical Care Co.

Receivables collection normalizing in H2 2018, positively impacting cash flows

As highlighted in the half-year results announcement, H1 2018 witnessed slight extension of receivable days outstanding due to slower receivables collection for the Distribution business as a result of extended holidays towards the end of the first half. As anticipated, receivables collection continues to normalize in the second half of the year, with a decline in receivable days outstanding in H2 2018. This continues to positively impact NMC's cash flow generation for the year.


KSA joint-venture progressing well, final agreement expected to be signed in early Q1 2019

Discussions with GOSI/Hassana for the finalization of the KSA JV continue to progress well, with the final agreement expected to be signed in early Q1 2019. The joint-venture was also showcased at the recently held Future Investment Initiative conference as one of the most prominent ongoing developments in the healthcare sector in KSA. As highlighted in our Capital Markets Day, the JV intends to double its initial bed capacity of c. 1,500 beds to approximately 3,000 in 3-5 years, followed by a further doubling of capacity to around 6,000 beds in 5-10 years.

Operations & Management (O&M) vertical continues to expand with signing of new contracts

NMC has signed a new O&M contract with the UAE Ministry of Presidential Affairs (MOPA) to manage a hospital in Seychelles. In addition, the Company continues to add a number of smaller, but strategic, O&M contracts in the UAE, which significantly support NMC's profile and visibility. A key recent example includes the signing of a contract to manage the medical clinic in Louvre Museum, Abu Dhabi. The Company similarly manages clinics in prominent locations such as the Grand Mosque in Abu Dhabi and the Court of the Crown Prince.

As highlighted earlier, in addition to providing some of the highest margin revenues, O&M contracts offer NMC the opportunity to gain experience in new market segments and geographies without risking its own capital. O&M contracts are now supporting business activity in other verticals as well. For example, both the Yemen and Kenya O&M contracts have become important sources of high-complexity patient referral to NMC Royal.

KPIs for management LTIP revised for better alignment with shareholder value creation

Based on the feedback received from key independent, institutional shareholders during recent meetings, NMC has opted to revise KPIs for management LTIP to better align with shareholder value creation. Consequently, the Remuneration Committee has determined to:

- Increase the EBITDA growth performance requirement for 2019 LTIP awards from 5% - 15% to 10% to 18% (CAGR) at threshold and maximum respectively.

- Introduce an additional underpin capturing the conversion of EBITDA to net income, to provide shareholders with an aggregate view on earnings, cash flow, and capital efficiency. Failure to meet the underpin will reduce the proportion of 2019 LTIP awards vesting by 50%.

The Remuneration Committee re-iterates that STIP and LTIP incentive targets are adjusted for acquisitions and other corporate activity on a case by case basis. Full disclosure of target adjustments will be provided in the 2018 Directors' Remuneration Report.

Mr Prasanth Manghat, Chief Executive Officer, commented:
"I am pleased that NMC's operations continue to perform very strongly, as reflected by our confidence in the reiterated financial guidance we have provided for 2018 and 2019. NMC's sustained growth is driven by a combination of 1) our strategy of offering complex, high value services well beyond simple multi-specialty, 2) maintaining an expansive footprint in our target markets, particular in the UAE where we are the only private player present in 6 of the 7 emirates and 3) offering healthcare for all, with no specific focus on one economic segment of patients. We continue to capitalize on new opportunities, as evidenced by the newly signed O&M contract with MOPA to manage a hospital in Seychelles. Furthermore, the importance NMC gives to views expressed by its owners is demonstrated by the revision of KPIs for management to bring them more in line with shareholder value creation. This was done in response to feedback we recently received from key independent shareholders."

BFN
Salma Hareb, Non Executive Director, bought 5,500 shares in the company on the 24th December 2018 at a price of 2699.07p. The Director now holds 12,100 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.sharesmagazine.co.uk